Small molecule therapeutics remain a cornerstone of modern medicine, providing a wide range of treatment options across oncology, cardiology, neurology, and infectious diseases. However, when these compounds are developed as sterile injectables, they face unique challenges that differ significantly from oral or topical dosage forms. Leukocare specializes in the stabilization and formulation of small molecules as sterile injectables—ensuring solubility, safety, chemical stability, and manufacturability from early development through global distribution.
Key Focus Areas
-
1. Feasibility assessment to identify solubility and stability risks early.
2. Optimization strategies guided by DoE and biostatistics for faster development.
3. Stability programs aligned with ICH requirements to support clinical trials and beyond.
4. Long-term partnership from early development through late-stage support, ensuring readiness for commercialization.